dc.contributor.author | Pritzlaff, Riley | |
dc.contributor.author | Groover, Sarah | |
dc.contributor.author | Sen, Ayantika | |
dc.contributor.author | Kaul, Anil | |
dc.contributor.author | Kaul, Rashmi | |
dc.date.accessioned | 2020-04-14T16:12:35Z | |
dc.date.available | 2020-04-14T16:12:35Z | |
dc.date.issued | 2019-02-22 | |
dc.identifier | ouhd_pritzlaff_IL-33expressionisaltered_2019 | |
dc.identifier.citation | Pritzlaff, R., Groover, S., Sen, A., Kaul, A., & Kaul, R. (2019, Feb. 22). IL-33 expression is altered in hepatitis C virus-related pathologies. Poster presented on Research Day at the Oklahoma State University Center for Health Sciences, Tulsa, OK. | |
dc.identifier.uri | https://hdl.handle.net/11244/323859 | |
dc.description.abstract | Hepatitis C virus (HCV) currently affects approximately 71 million people worldwide and causes extensive liver damage that can transition into hepatocellular carcinoma (HCC), a deadly malignant liver cancer. Unfortunately, patients tend to seek diagnostic testing late, when more severe symptoms exist, indicating advanced disease with severe fibrosis. There is a gap in knowledge about the immunologic process of HCV-induced fibrosis and cirrhosis development. Interleukin-33 (IL-33) is a cytokine implicated in various inflammatory and fibrotic diseases. We hypothesize that IL-33 plays a role in the pathogenesis of HCV, particularly in fibrosis and cirrhosis development leading to malignant transformation and thus may serve as an inflammatory biomarker. We studied livers from normal subjects - no liver-related diagnoses (n=6), subjects with HCV-cirrhosis (n=7), and subjects with HCV/HCC (n=7). We performed immunohistochemistry on paraffin-embedded liver tissue sections using a human IL-33 antibody and DAB staining system. To quantify our results, we performed image analyses quantifying IL-33 chromogen stain using an algorithm to calculate the signal strength of an image to determine the amount of antibody-specific chromogen per pixel, expressed in energy units per pixel (eu/px). We found that IL-33 is normally expressed in human hepatocytes; it is expressed at higher levels in HCV-cirrhosis patients and at lower levels in HCV-HCC patients. We plan to expand this study by including more patients in the future. | |
dc.format | application/pdf | |
dc.language | en_US | |
dc.publisher | Oklahoma State University Center for Health Sciences | |
dc.rights | The author(s) retain the copyright or have the right to deposit the item giving the Oklahoma State University Library a limited, non-exclusive right to share this material in its institutional repository. Contact Digital Resources and Discovery Services at lib-dls@okstate.edu or 405-744-9161 for the permission policy on the use, reproduction or distribution of this material. | |
dc.title | IL-33 expression is altered in hepatitis C virus-related pathologies | |
osu.filename | ouhd_pritzlaff_IL-33expressionisaltered_2019.pdf | |
dc.type.genre | Presentation | |
dc.type.material | Text | |